Mirum Pharmaceuticals, Inc.
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
MIRM$94.42+1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity
(In thousands, except share amounts)
| Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensive Income (Loss) · TotalStockholders’Equity (Deficit) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||||
| Balance as of December 31, 2025 | 51,896,391 | $5 | $981,878 | $(667,544) | $351 | $314,690 | |||||
| Issuance of common stock and pre-funded warrants in private placement, net of issuance costs of $8,600 | 3,385,149 | — | 259,948 | — | — | 259,948 | |||||
| Issuance of common stock in connection with asset acquisition | 4,404,190 | 1 | 415,270 | — | — | 415,271 | |||||
| Stock-based compensation in connection with asset acquisition | 112,872 | — | 10,643 | — | — | 10,643 | |||||
| Issuance of common stock in connection with equity award plans | 1,127,563 | — | 10,131 | — | — | 10,131 | |||||
| Stock-based compensation | — | — | 22,345 | — | — | 22,345 | |||||
| Net loss | — | — | — | (790,155) | — | (790,155) | |||||
| Other comprehensive loss | — | — | — | — | (379) | (379) | |||||
| Balance as of March 31, 2026 | 60,926,165 | $6 | $1,700,215 | $(1,457,699) | $(28) | $242,494 | |||||
| Issuance of common stock in connection with equity award plans | 560,812 | — | 11,304 | — | — | 11,304 | |||||
| Issuance of common stock in connection with employee stock purchase plan | 47,162 | — | 2,859 | — | — | 2,859 | |||||
| Conversion of convertible notes, net | 31 | — | 1 | — | — | 1 | |||||
| Exchange and repurchase of convertible notes maturing in 2029 | — | — | (558,901) | — | — | (558,901) | |||||
| Shares issued in connection with the exchange and repurchase of convertible notes maturing in 2029 | 3,220,529 | — | 329,089 | — | — | 329,089 | |||||
| Stock-based compensation | — | — | 30,605 | — | — | 30,605 | |||||
| Net loss | — | — | — | (67,227) | — | (67,227) | |||||
| Other comprehensive loss | — | — | — | — | (646) | (646) | |||||
| Balance as of June 30, 2026 | 64,754,699 | $6 | $1,515,172 | $(1,524,926) | $(674) | $(10,422) | |||||
| Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome (Loss) · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2024 | 48,338,096 | $5 | $870,189 | $(644,181) | $(373) | $225,640 |
| Issuance of common stock in connection with equity award plans | 1,112,939 | — | 6,359 | — | — | 6,359 |
| Conversion of convertible notes, net | 188 | — | 6 | — | — | 6 |
| Stock-based compensation | — | — | 15,813 | — | — | 15,813 |
| Net loss | — | — | — | (14,677) | — | (14,677) |
| Other comprehensive income | — | — | — | — | 115 | 115 |
| Balance as of March 31, 2025 | 49,451,223 | $5 | $892,367 | $(658,858) | $(258) | $233,256 |
| Issuance of common stock in connection with equity award plans | 547,323 | — | 6,575 | — | — | 6,575 |
| Issuance of common stock in connection with employee stock purchase plan | 59,752 | — | 2,113 | — | — | 2,113 |
| Conversion of convertible notes, net | 94 | — | 3 | — | — | 3 |
| Stock-based compensation | — | — | 18,462 | — | — | 18,462 |
| Net loss | — | — | — | (5,861) | — | (5,861) |
| Other comprehensive income | — | — | — | — | 610 | 610 |
| Balance as of June 30, 2025 | 50,058,392 | $5 | $919,520 | $(664,719) | $352 | $255,158 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.